M A Sherman Selected Research

Interferons

1/2019

[Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M A Sherman Research Topics

Disease

2	Multiple Sclerosis 01/2019 - 01/2017
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022
1	Autonomic Nervous System Diseases (Dysautonomia) 01/2022
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2021
1	Ischemic Stroke 01/2015
1	Brain Infarction 01/2015
1	Infections 06/2004
1	Lymphoma (Lymphomas) 03/2001
1	Inflammation (Inflammations) 02/2001
1	Lung Diseases (Lung Disease) 09/2000
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 09/2000

Drug/Important Bio-Agent (IBA)

2	Pharmaceutical PreparationsIBA 01/2022 - 01/2019
2	Interferon beta-1a FDA Link 01/2019 - 01/2017
2	Peptides (Polypeptides)IBA 06/2004 - 09/2000
1	Anti-Anxiety Agents (Anxiolytics)IBA 01/2022
1	Trimeprazine (Alimemazine)IBA 01/2022
1	HLA-DRB1*03:01 antigenIBA 01/2021
1	InterferonsIBA 01/2019
1	Biosimilar PharmaceuticalsIBA 01/2019
1	AntioxidantsIBA 01/2015
1	theta-defensinIBA 06/2004
1	EpitopesIBA 03/2001
1	Proteins (Proteins, Gene)FDA Link 03/2001
1	InterleukinsIBA 02/2001
1	Surface-Active Agents (Surfactants)IBA 09/2000
1	LipidsIBA 09/2000

Therapy/Procedure

3	Therapeutics 01/2022 - 09/2000
1	Subcutaneous Injections 01/2017